我国核药产业发展透视及建议OA

Objective To analyze the application status and development prospects of China's radiopharmaceutical industry.Methods Literatures and pharmaceutical databases were reviewed,the competitive landscape,market size,and development trends of the global radiopharmaceutical market were systematically summarized.The focus was placed on analyzing the current development status,market structure,research and development pipeline,and investment and financing dynamics of China's radiopharmaceutical industry.Core driving factors such as policy environment,market demand,and the construction of nuclear medicine department were examined,and key issues and challenges in the industrial development were identified.Results The global radiopharmaceutical industry was growing rapidly,with therapeutic radiopharmaceuticals becoming the primary growth driver.China's radiopharmaceutical industry chain holds broad market prospects such as product research and development,policy-driven,and clinical applications.The market was highly concentrated,with diagnostic radiopharmaceuticals dominating,though the proportion of therapeutic radiopharmaceuticals was gradually increasing.Domestic research and development pipelines focused on cutting-edge technologies such as integration of diagnosis and treatment and α-emitting,with active industry investment and financing.However,the industry still faced challenges including high barriers to clinical application,constraints in key supply chain segments,shortage of professional talent,and the need for enhanced policy coordination.In response to these issues,targeted recommendations were proposed,including planning top-level planning,accelerating approval processes,promoting technological innovation,and facilitating market application.Conclusion A comprehensive study of the radiopharmaceutical industry chain contributes to accelerating the enhancement of the competitiveness of China's radiopharmaceutical industry and helping regulatory authorities promote healthy,standardized,and orderly development of the radiopharmaceutical industry.